Genentech, a member of the Roche Group, announced that it is presenting new long-term follow-up results and subanalyses from clinical trials of its approved therapies, as well as data on investigational medicines from its broad blood cancer portfolio, at the European Hematology Association 2022 Congress in Vienna.
June 10, 2022
· 26 min read